Xvivo Perfusion AB Stock price

Equities

XVIVO

SE0004840718

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm 07:59:32 2024-03-28 am EDT 5-day change 1st Jan Change
275 SEK 0.00% Intraday chart for Xvivo Perfusion AB -2.65% -16.54%
Sales 2023 598M 56.12M Sales 2024 * 804M 75.56M Capitalization 8.66B 814M
Net income 2023 91M 8.55M Net income 2024 * 77M 7.23M EV / Sales 2023 16.5 x
Net cash position 2023 515M 48.34M Net cash position 2024 * 454M 42.66M EV / Sales 2024 * 10.2 x
P/E ratio 2023
107 x
P/E ratio 2024 *
120 x
Employees 150
Yield 2023 *
-
Yield 2024 *
-
Free-Float 75.13%
More Fundamentals * Assessed data
Dynamic Chart
Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Nordic Shares Moved Upward Thursday; Nokia Topped Leaders DJ
Transcript : Xvivo Perfusion AB, 2023 Earnings Call, Jan 25, 2024
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss DJ
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial CI
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee CI
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue MT
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial MT
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial CI
Transcript : Xvivo Perfusion AB, Q2 2023 Earnings Call, Jul 13, 2023
More news
1 day+0.36%
1 week-2.65%
Current month+1.85%
1 month+7.21%
3 months-16.29%
6 months-0.90%
Current year-16.54%
More quotes
1 week
271.50
Extreme 271.5
284.00
1 month
256.50
Extreme 256.5
294.00
Current year
252.50
Extreme 252.5
343.50
1 year
205.50
Extreme 205.5
343.50
3 years
127.80
Extreme 127.8
459.00
5 years
70.30
Extreme 70.3
459.00
10 years
33.40
Extreme 33.4
459.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 12-08-31
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 57 20-09-30
Members of the board TitleAgeSince
Director/Board Member 60 16-04-30
Chairman 65 -
Director/Board Member 69 19-12-31
More insiders
Date Price Change Volume
24-03-28 275 0.00% 8 886
24-03-27 275 +0.73% 14,401
24-03-26 273 -0.55% 22,965
24-03-25 274.5 -1.44% 19,647
24-03-22 278.5 -1.42% 18,482

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company's product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
275 SEK
Average target price
382.6 SEK
Spread / Average Target
+39.13%
Consensus
  1. Stock
  2. Equities
  3. Stock Xvivo Perfusion AB - Nasdaq Stockholm